News | June 02, 2021
Lasa Supergenerics FY21 profit up 521%
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Adjusted PAT declined 18.8% YoY
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Financial support is being provided as a grant from the Government of India
Subscribe To Our Newsletter & Stay Updated
